Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ANIP Relative to the S&P 500

ANIP Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the ANI Pharmaceuticals, Inc. (NASD:ANIP) seasonal charts above shows that a Buy Date of March 25 and a Sell Date of June 26 has resulted in a geometric average return of 6.9% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 19.77% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

To download ANIP seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ANIP